Larimar Therapeutics, Inc. financial data

Symbol
LRMR on Nasdaq
Industry
Pharmaceutical Preparations
Location
Three Bala Plaza East. Suite 506, Bala Cynwyd, PA
State of incorporation
DE
Fiscal year end
December 31
Former names
ZAFGEN, INC. (to 5/19/2020), ZAFGEN INC (to 11/3/2008)
Latest financial report
10-K - Q4 2024 - Mar 24, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.17K % -10.5%
Debt-to-equity 11.3 % -13.5%
Return On Equity -39.7 % -2.19%
Return On Assets -35.6 % -3.82%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 64M shares +0.36%
Common Stock, Shares, Outstanding 63.8M shares +45.3%
Entity Public Float 314M USD
Common Stock, Value, Issued 64K USD +48.8%
Weighted Average Number of Shares Outstanding, Basic 61.3M shares +39.5%
Weighted Average Number of Shares Outstanding, Diluted 61.3M shares +39.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 73.3M USD +165%
General and Administrative Expense 17.6M USD +25%
Operating Income (Loss) -90.9M USD -118%
Nonoperating Income (Expense) 10.3M USD +114%
Net Income (Loss) Attributable to Parent -80.6M USD -118%
Earnings Per Share, Basic -1.32 USD/shares -57.1%
Earnings Per Share, Diluted -1.32 USD/shares -57.1%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 33.2M USD +24.2%
Cash, Cash Equivalents, and Short-term Investments 184M USD +111%
Assets, Current 195M USD +117%
Property, Plant and Equipment, Net 881K USD +28.8%
Operating Lease, Right-of-Use Asset 2.84M USD -7.8%
Other Assets, Noncurrent 596K USD -9.56%
Assets 200M USD +109%
Accounts Payable, Current 2.42M USD +88.9%
Employee-related Liabilities, Current 3.25M USD +37.6%
Accrued Liabilities, Current 20.9M USD +183%
Liabilities, Current 24.4M USD +156%
Operating Lease, Liability, Noncurrent 4.06M USD -13.8%
Liabilities 28.4M USD +99.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax 148K USD +82.7%
Retained Earnings (Accumulated Deficit) -269M USD -42.7%
Stockholders' Equity Attributable to Parent 172M USD +110%
Liabilities and Equity 200M USD +109%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -10.4M USD -37.9%
Net Cash Provided by (Used in) Financing Activities 162M USD
Net Cash Provided by (Used in) Investing Activities -68.4M USD -174%
Common Stock, Shares Authorized 115M shares 0%
Common Stock, Shares, Issued 63.8M shares +45.3%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 83.4M USD -1.56%
Deferred Tax Assets, Valuation Allowance 173M USD +22%
Deferred Tax Assets, Gross 174M USD +21.9%
Operating Lease, Liability 5.12M USD -7.74%
Depreciation 80K USD +2.56%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -80.5M USD -119%
Lessee, Operating Lease, Liability, to be Paid 6.43M USD -12.2%
Property, Plant and Equipment, Gross 2.42M USD +27%
Operating Lease, Liability, Current 1.06M USD +26.6%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.47M USD +4.99%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.54M USD +11.8%
Operating Lease, Weighted Average Discount Rate, Percent 0.11 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.31M USD -26.1%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.27M USD -4.59%
Deferred Tax Assets, Operating Loss Carryforwards 50.2M USD +11%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.19M USD +6.35%
Preferred Stock, Shares Outstanding 0 shares
Share-based Payment Arrangement, Expense 8.8M USD +15.5%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%